Starting Treatment

How to get your patients started with AMVUTTRA®

Choose any of the 3 methods to complete the Start Form. Once enrolled, Alnylam Assist® can provide support for patients throughout the treatment process.

Computer icon

Electronic Start Form

Complete and submit the Electronic Start Form online with your patient

Pen and paper icon

DocuSign Start Form

Begin the Start Form and send to your patient over email to complete via DocuSign

Printer icon

Downloadable Start Form

Print, complete with your patient, and fax the Start Form to 1-833-256-2747

Alnylam Assist offers support services to guide your patients through treatment with AMVUTTRA, including:

Help with ordering AMVUTTRA via specialty distributor or specialty pharmacy

Financial assistance programs for eligible patients.a These may include:

  • Alnylam Assist Patient Assistance Program (PAP): Provides AMVUTTRA at no cost to eligible patients, primarily the uninsured, who meet specified financial criteria
  • Alnylam Assist Commercial Copay Programb: Covers certain out-of-pocket costs for eligible patients with commercial insurance

AMVUTTRA coverage, coding, and reimbursement education and patient-specific benefit verification

aPatients must meet specified eligibility criteria to qualify for assistance. Alnylam reserves the right to make eligibility determinations and to modify or discontinue any program at any time.

bPatients with Medicare, Medicaid, or other government-sponsored insurance are not eligible for the Alnylam Assist Commercial Copay Program. Out-of-pocket costs for the administration of AMVUTTRA will not be covered for patients residing where it is prohibited by law or where otherwise restricted.

8AM–6PM, Monday–Friday
Printer icon 1-833-256-2747
To learn more, visit
Alnylam Assist® brochure
Alnylam Assist® brochure

Alnylam Assist® brochure

Learn more about patient support available through Alnylam Assist

Patient Access and Affordability

Four-times-a-year AMVUTTRA is accessible and affordable for most patients, regardless of insurance type. AMVUTTRA is HCP-administered once every 3 months.

  • 99% of patients have confirmed coverage for AMVUTTRAc
  • >65% of patients treated with AMVUTTRA have no out-of-pocket costsc
  • For many patients with commercial insurance or Medicare, AMVUTTRA is covered under the medical benefit and not the pharmacy benefit

cAs of December 29, 2023.

Find a treatment center
Find a treatment center

Locate a treatment center closest to your patients.

Stay informed
Stay informed

Receive helpful information for you and your patients.

Important Safety Information and Indication

Important Safety Information

Reduced Serum Vitamin A Levels and Recommended Supplementation

AMVUTTRA® (vutrisiran) treatment leads to a decrease in serum vitamin A levels.

Supplementation at the recommended daily allowance (RDA) of vitamin A is advised for patients taking AMVUTTRA. Higher doses than the RDA should not be given to try to achieve normal serum vitamin A levels during treatment with AMVUTTRA, as serum vitamin A levels do not reflect the total vitamin A in the body.

Patients should be referred to an ophthalmologist if they develop ocular symptoms suggestive of vitamin A deficiency (e.g., night blindness).

Adverse Reactions

The most common adverse reactions that occurred in patients treated with AMVUTTRA were pain in extremity (15%), arthralgia (11%), dyspnea (7%), and vitamin A decreased (7%).


AMVUTTRA is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

For additional information about AMVUTTRA, please see the full Prescribing Information.